Allitinib is primarily used in the treatment of non-small cell lung cancer (NSCLC), particularly in cases where the cancer has specific mutations in the epidermal growth factor receptor (EGFR). It functions as a tyrosine kinase inhibitor, targeting and blocking the activity of EGFR, which is often overactive in certain types of cancer. By inhibiting this receptor, Allitinib helps to slow down or stop the growth and spread of cancer cells. It is especially effective in patients who have developed resistance to other EGFR inhibitors, offering a therapeutic option for those with limited treatment alternatives. Additionally, Allitinib has shown promise in clinical trials for its potential use in other cancers where EGFR mutations play a significant role, expanding its application in oncology.